DFTX Stock — Definium Therapeutics, Inc.

Definium Therapeutics, Inc. (DFTX)

Updated October 16, 2026.

DFTX is a Stock. Total return is 851.1% over the past 9.9 years, 541.6 points ahead of SPY at 309.5%.

Definium Therapeutics is a clinical biopharmaceutical company developing novel treatments for brain health disorders, with lead candidates DT120 in phase 3 trials for generalized anxiety disorder and major depressive disorder, and DT402 in phase 2a trials for autism spectrum disorder. The company does not currently distribute dividends. As an early-stage clinical biotech company, it is oriented toward potential capital appreciation rather than income generation.

DFTX performance versus SPY

Price and return data through 2026-10-16.

Total return is 851.1% over the past 9.9 years, 541.6 points ahead of SPY at 309.5%. Over the past year its total return — price change plus distributions reinvested — is 169.5%. Its deepest 1-year drawdown was 33.7%.

DFTX key facts

Asset type

Stock

Asset class

Equity

Inception date

11/15/2016

Distribution frequency

None

Last close

$32.10 (as of 2026-10-16)

Market cap

$4,313,179,095

Average volume

1934241.0

Beta

2.194

Payout ratio

0.0%

EPS

$-3.43

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DFTX risks and drawbacks

The deepest 1-year drawdown on record here is 33.7%.

Who may consider DFTX — and who may not

It is a weaker fit for investors who need monthly cash flow (DFTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on DFTX

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions